COSTA MESA, Calif., Aug. 4, 2016 /PRNewswire-iReach/ -- California CRO WCCT Global was recently featured in a publicationregarding the successful results from a completed immunology clinical trial hosted at the company's multi-phase CPU in Costa Mesa, CA. Unlike most other clinical research sites, WCCT ensures that a board-certified specialist
Photo - http://photos.prnewswire.com/prnh/20160801/394781LOGO
WCCT took part in a Phase 3, multi-site immunology clinical trial for patients with Primary Immunodeficiency Diseases (PIDD). WCCT was able to successfully enroll patients at their Phase I-IV clinical pharmacology unit and make valuable contributions to the success of that program. The results of this program have been published in the May 2016 issue of Journal of Clinical Immunology, under the title "Long-Term Tolerability, Safety, and Efficacy of Recombinant Human Hyaluronidase-Facilitated Subcutaneous Infusion of Human Immunoglobulin for Primary Immunodeficiency." The results concluded that long-term replacement therapy with IGHy was safe and effective in over 80 pediatric and adult subjects with PIDD.
WCCT Global's President, Jon Rojas, had this to say about the company's role in these successful programs: "I strongly feel that our ability to make meaningful contributions to research programs in a variety of diseases is a result of our commitment to being therapeutically better than other CROs and research sites. There is a true value in assigning a board-certified specialist to act as the PI or sub-PI for a program, as opposed to a PI with no therapeutic focus. Thus, WCCT has greater flexibility in the types of programs we can take on and conduct, surpassing the expectations of our clients." WCCT looks to continue its work in multiple therapeutic areas both as a CRO and at its multiple research sites across the Southern California region.
About WCCT Global
WCCT Global is a multi-site, full service pharmaceutical contract research organization (CRO) of outsourced early drug development and late phase CRO services to the pharmaceutical, biotechnology and medical device industries. The WCCT Global vision, "With compassion for people, we strive for tomorrow's therapies to be available today" truly exemplifies the focus and reason for our cutting edge work both in our clinics and throughout our operations. As a drug development partner, WCCT Global collaborates with domestic and foreign innovator companies who need regulatory, program management, patient recruitment, data management and strategic consulting support, with an emphasis on overseeing and executing trials in special disease populations, pediatric populations, ethno-bridging, and cardiac safety. WCCT has extensive experience with healthy volunteer studies including First-in-Human (FIH), as well as specific therapeutic expertise in Allergy, Asthma, HCV, Ophthalmology, Renal, and Vaccines.
Media Contact: Salvador Solis, WCCT Global, 7146881500x2261, email@example.com
News distributed by PR Newswire iReach: https://ireach.prnewswire.com
SOURCE WCCT Global
Subscribe to our Free Newsletters!
Angiogenesis is the process of formation of new blood vessels from pre-existing blood vessels. It ...
Aniridia is a genetic eye disorder in which the iris is partially or entirely absent. It is ...
Cachexia refers to severe muscle and fat loss, anorexia and marked weight loss due to an underlying ...View All